Rep. Julia Letlow Purchases Shares of AstraZeneca PLC (NASDAQ:AZN)

Representative Julia Letlow (R-Louisiana) recently bought shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on January 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in AstraZeneca stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

AstraZeneca Price Performance

AZN traded down $2.35 on Thursday, hitting $93.99. 9,146,390 shares of the company’s stock were exchanged, compared to its average volume of 6,975,408. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $96.51. The stock has a market cap of $291.51 billion, a price-to-earnings ratio of 31.23, a P/E/G ratio of 1.56 and a beta of 0.34. The firm has a 50-day moving average price of $91.12 and a 200-day moving average price of $82.50. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, November 6th. The company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a net margin of 16.17% and a return on equity of 32.89%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.08 earnings per share. As a group, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Institutional Trading of AstraZeneca

Several institutional investors have recently added to or reduced their stakes in AZN. Allspring Global Investments Holdings LLC boosted its holdings in AstraZeneca by 10.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 191,518 shares of the company’s stock valued at $16,156,000 after purchasing an additional 17,548 shares during the period. Canandaigua National Bank & Trust Co. increased its holdings in AstraZeneca by 19.7% during the 2nd quarter. Canandaigua National Bank & Trust Co. now owns 19,804 shares of the company’s stock worth $1,384,000 after purchasing an additional 3,260 shares during the period. Voya Investment Management LLC raised its position in AstraZeneca by 68.2% in the 3rd quarter. Voya Investment Management LLC now owns 1,899,502 shares of the company’s stock valued at $145,730,000 after purchasing an additional 770,417 shares in the last quarter. Robbins Farley purchased a new position in shares of AstraZeneca in the 2nd quarter valued at about $1,857,000. Finally, Jennison Associates LLC grew its position in shares of AstraZeneca by 15.2% during the second quarter. Jennison Associates LLC now owns 12,167,365 shares of the company’s stock worth $850,255,000 after buying an additional 1,605,133 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday, October 16th. HSBC reaffirmed a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a report on Wednesday, December 10th. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, October 8th. Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Finally, Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of $95.75.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.